{
    "address1": "177 East Colorado Boulevard",
    "address2": "Suite 700",
    "city": "Pasadena",
    "state": "CA",
    "zip": "91105",
    "country": "United States",
    "phone": "626 304 3400",
    "fax": "626 304 3401",
    "website": "https://arrowheadpharma.com",
    "industry": "Biotechnology",
    "sector": "Healthcare",
    "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
    "fullTimeEmployees": 397,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Christopher R. Anzalone Ph.D.",
            "age": 53,
            "title": "CEO, Pres & Director",
            "yearBorn": 1969,
            "fiscalYear": 2022,
            "totalPay": 1649420,
            "exercisedValue": 996462,
            "unexercisedValue": 14937168
        },
        {
            "maxAge": 1,
            "name": "Mr. Kenneth A. Myszkowski",
            "age": 56,
            "title": "Chief Financial Officer",
            "yearBorn": 1966,
            "fiscalYear": 2022,
            "totalPay": 761552,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Patrick  O'Brien J.D., PharmD",
            "age": 58,
            "title": "COO, Gen. Counsel & Sec.",
            "yearBorn": 1964,
            "fiscalYear": 2022,
            "totalPay": 749863,
            "exercisedValue": 172200,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. James C. Hamilton M.D., MBA",
            "age": 44,
            "title": "Chief of Discovery & Translational Medicine",
            "yearBorn": 1978,
            "fiscalYear": 2022,
            "totalPay": 676814,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Tracie  Oliver",
            "title": "Chief Commercial Officer",
            "fiscalYear": 2022,
            "totalPay": 449579,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Mark M. Davis Ph.D.",
            "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Vincent  Anzalone CFA",
            "title": "Head of Investor Relations & VP",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Howard  Lovy",
            "title": "Director of Communications",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Mark  Seefeld",
            "age": 68,
            "title": "Head of Toxicology & VP",
            "yearBorn": 1954,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Javier  San Martin M.D.",
            "age": 57,
            "title": "Chief Medical Officer",
            "yearBorn": 1965,
            "fiscalYear": 2021,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 9,
    "boardRisk": 8,
    "compensationRisk": 3,
    "shareHolderRightsRisk": 1,
    "overallRisk": 4,
    "governanceEpochDate": 1693526400,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 30.22,
    "open": 30.25,
    "dayLow": 29.78,
    "dayHigh": 30.7,
    "regularMarketPreviousClose": 30.22,
    "regularMarketOpen": 30.25,
    "regularMarketDayLow": 29.78,
    "regularMarketDayHigh": 30.7,
    "payoutRatio": 0.0,
    "beta": 0.99343,
    "forwardPE": -10.794224,
    "volume": 723109,
    "regularMarketVolume": 723109,
    "averageVolume": 900193,
    "averageVolume10days": 941010,
    "averageDailyVolume10Day": 941010,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 1300,
    "askSize": 800,
    "marketCap": 3205070592,
    "fiftyTwoWeekLow": 23.09,
    "fiftyTwoWeekHigh": 42.48,
    "priceToSalesTrailing12Months": 12.509399,
    "fiftyDayAverage": 31.6894,
    "twoHundredDayAverage": 32.64165,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 3116317696,
    "profitMargins": -0.70685995,
    "floatShares": 103938525,
    "sharesOutstanding": 107193000,
    "sharesShort": 6057276,
    "sharesShortPriorMonth": 5160475,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.056500003,
    "heldPercentInsiders": 0.0496,
    "heldPercentInstitutions": 0.70739996,
    "shortRatio": 6.62,
    "shortPercentOfFloat": 0.0674,
    "bookValue": 3.406,
    "priceToBook": 8.778626,
    "lastFiscalYearEnd": 1664496000,
    "nextFiscalYearEnd": 1696032000,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -181107008,
    "trailingEps": -1.69,
    "forwardEps": -2.77,
    "pegRatio": -2.73,
    "lastSplitFactor": "1:10",
    "lastSplitDate": 1321488000,
    "enterpriseToRevenue": 12.163,
    "enterpriseToEbitda": -18.417,
    "exchange": "NMS",
    "quoteType": "EQUITY",
    "symbol": "ARWR",
    "underlyingSymbol": "ARWR",
    "shortName": "Arrowhead Pharmaceuticals, Inc.",
    "longName": "Arrowhead Pharmaceuticals, Inc.",
    "firstTradeDateEpochUtc": 756052200,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 29.9,
    "targetHighPrice": 90.0,
    "targetLowPrice": 27.0,
    "targetMeanPrice": 58.54,
    "targetMedianPrice": 60.0,
    "recommendationMean": 2.1,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 13,
    "totalCash": 451703008,
    "totalCashPerShare": 4.214,
    "ebitda": -169208000,
    "totalDebt": 345798016,
    "quickRatio": 6.45,
    "currentRatio": 6.695,
    "totalRevenue": 256212992,
    "debtToEquity": 90.526,
    "revenuePerShare": 2.408,
    "returnOnAssets": -0.14579001,
    "returnOnEquity": -0.4303,
    "grossProfits": 243231000,
    "freeCashflow": -226575744,
    "operatingCashflow": -197370000,
    "revenueGrowth": -0.512,
    "grossMargins": 1.0,
    "ebitdaMargins": -0.66042,
    "operatingMargins": -0.70449996,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "GNOM"
    ]
}